ClinConnect ClinConnect Logo
Search / Trial NCT06694272

Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · Nov 15, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on understanding early forms of age-related macular degeneration (AMD), a common eye condition that can lead to vision problems. Researchers want to identify changes in the eye that happen before more serious vision loss occurs. By studying these early signs, they hope to find better ways to treat AMD and slow its progression to more advanced stages. The trial aims to explore how certain tests can detect these early changes in vision function and eye structure.

To participate in this study, individuals must be at least 18 years old and have good corrected vision (10/10) in both eyes. They should also show specific early signs of AMD, such as certain types of small yellow-white deposits in the retina. However, people with more advanced eye issues or certain neurological conditions that could affect their ability to complete tests may not be eligible. Those who take part can expect to undergo various visual tests to help researchers gather important information about how AMD affects vision at its early stages. This study is not yet recruiting participants, but it represents a crucial step in improving care for people with AMD.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient over 18 years of age
  • Corrected visual acuity 10/10 in each eye
  • * Presence of retinal alteration(s) compatible with early (presence of macular drusen \< 125 μm) or intermediate (macular drusen \> 125 μm or pigmentary abnormalities) AMD in at least one of the two eyes :
  • Conventional "soft" or "hard" drusen
  • Cuticular drusen
  • Reticulated pseudo-drusen
  • Exclusion Criteria:
  • Presence of geographic atrophy, even incipient, in one or both eyes
  • Presence of patent or latent neovascularization visible on OCT b-scan or OCT-A in one or both eyes
  • Compatibility of retinal signs with a "probable" differential diagnosis (bestrophinopathies, familial drusen, fundus flavimaculatus, fundus albipunctatus, hypovitaminosis A) in one or both eyes.
  • Oculomotor pathology that may prevent proper performance of functional tests: nystagmus, oculomotor paralysis, in one or both eyes
  • Neurological/neurodegenerative pathology that may prevent adequate performance of functional tests: advanced Parkinsonian syndromes, Benson's disease, Alzheimer's disease with visuomotor apraxia
  • Other ophthalmological pathology that may affect anatomical and functional measurements: hypertonia / glaucoma or other optic neuropathy, media disorder causing reduced visual acuity, refraction \< -6.00D or \> +6.00D
  • Other medical conditions preventing examinations or imaging (tremors, etc.)

About Fondation Ophtalmologique Adolphe De Rothschild

The Fondation Ophtalmologique Adolphe de Rothschild is a leading French institution dedicated to advancing ophthalmic research and patient care. Renowned for its commitment to innovation in eye health, the foundation conducts cutting-edge clinical trials aimed at improving treatments for various ocular conditions. With a multidisciplinary team of experts, the foundation collaborates with academic and industry partners to enhance understanding of eye diseases and develop novel therapeutic solutions, ultimately striving to improve patient outcomes and quality of life in ophthalmology.

Locations

Paris, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported